CARsgen Therapeutics' Satricabtagene Autoleucel Granted Priority Review by China's NMPA for Advanced Gastric Cancer Therapy
I'm PortAI, I can summarize articles.
CARsgen Therapeutics Holdings Ltd. announced that its product, Satricabtagene Autoleucel (Satri-cel), has received priority review from China's National Medical Products Administration (NMPA) for treating Claudin18.2-positive advanced gastric cancer in patients unresponsive to previous therapies. This status aims to expedite the regulatory process, potentially allowing for a quicker market introduction of this innovative CAR T-cell therapy, underscoring CARsgen's dedication to addressing unmet clinical needs.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments